KMC Speciality Hospitals (India) Ltd

Key approvals

• Trichy expansion approved: ~500 beds; Rs 486 crore; two phases Q4 FY28, Q2 FY30.
• Bengaluru M&C hospital on leased premises: ~91 beds; Rs 33 crore; operations in Q2 FY28.
• Adjoining ~1 acre freehold land in Trichy approved; cost Rs 62.50 crore (May 29, 2026 disclosure).
• Cost Auditor appointed: M/s. G Sugumar & Co for FY2026-27; date 14 Aug 2026.
• Board approval date: 14 August 2026.

Financial performance

• Standalone unaudited results for quarter ended 30 Jun 2026.
• Single segment: Medical and Healthcare Services; auditor's report unmodified.
• Total income ₹9,171.72 lakh; Profit before tax ₹2,243.82 lakh; Profit after tax ₹1,657.31 lakh.
• EPS: ₹0.46; Board approved results on 14 Aug 2026; Audit Committee reviewed.

Encumbrance details

• Target: KMC Speciality Hospitals (India) Limited.
• Acquirer: Catalyst Trusteeship Limited (Debenture Trustee for Prospera Healthcorp Pvt. Ltd.).
• Acquirer not part of promoter/promoter group.
• TC listed on BSE Limited.
• Pre-acquisition holding: acquirer NIL voting rights and encumbrances.
• Encumbrance details: Pledge 74,10,831 SKMCIL shares (14.53%); Non-disposal 1,65,32,316 shares (32.40%).
• Total encumbrance: 2,39,43,147 SKMCIL shares, 46.93% fully diluted.
• Mode: Indirect encumbrance over SKMCIL shares to Debenture Trustee.
• Dates: Pledge July 7, 2026; Non-disposal July 6, 2026.
• Encumbrance confirmed August 7, 2026.
• Equity capital before/after: INR 16,30,85,000; 16,30,85,000 shares; unchanged.
• Note: Encumbrance arises via SKMCIL; not direct over TC shares.

Meeting Details

• Board meeting on 14 August 2026 to consider unaudited quarterly results for quarter ended 30 June 2026.
• Time and venue not disclosed.

Key Agenda Items

• Approval of unaudited financial results for quarter ended 30 June 2026.

Other Notes

• No additional material governance actions disclosed beyond the unaudited results.

Dematerialisation status

• Dematerialisation requests in the reporting quarter were confirmed to depositories (accepted/rejected) by the Registrar.
• Securities dematerialised have been listed on the stock exchanges where previously listed.
• Physical certificates for dematerialisation were mutilated and cancelled; depository name substituted as registered owner within 15 days.

Internal auditor appointment

• M/s. Grant Thornton Bharat LLP appointed as internal auditor.
• Effective date: 29 May 2026; term: FY 2026-27.
• Reason: appointment approved by the Board.
• Profile: professional services firm with assurance, consulting, tax, risk, and digital services.
• No director relationship disclosure applicable.

Margins and costs

• 📊 Employee benefit expense rose to ₹10,701.69 lakh in FY26 from ₹8,914.55 lakh.
• 📊 Other expenses increased to ₹6,302.36 lakh from ₹3,160.34 lakh.
• 📊 Finance costs declined to ₹507.59 lakh from ₹594.50 lakh.
• 📊 Depreciation and amortisation expense increased to ₹2,453.14 lakh from ₹1,895.25 lakh.
• 📊 Current tax expense rose to ₹1,628.92 lakh from ₹1,017.63 lakh.

Balance sheet and cash

• 📊 Cash and cash equivalents were ₹756.26 lakh at 31 March 2026.
• 📊 Trade receivables were ₹5,002.07 lakh at 31 March 2026.
• 📊 Inventories were ₹387.93 lakh at 31 March 2026.
• 📊 Total borrowings were ₹1,263.70 lakh, including current and non-current liabilities.
• 📊 Total equity stood at ₹29,968.63 lakh at 31 March 2026.
• 📊 Net cash from operating activities was ₹9,121.12 lakh in FY26.
• 📊 Net cash used in investing activities was ₹1,095.09 lakh in FY26.
• 📊 Net cash used in financing activities was ₹307.59 lakh in FY26.

Operations

• 📍 The company operates in a single segment: Medical and Healthcare Services.
• 🧱 Balance sheet and cash flow statement were provided as annexures.
• 📍 The board approved the standalone audited results on 29 May 2026.

Audit

• 📍 Statutory auditors issued an unmodified opinion on FY26 standalone financial statements.
• 📍 Auditors also issued an unmodified review report for Q4 FY26.